Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels.

American journal of respiratory and critical care medicine·2023
Same author

Label-Free Time-of-Flight Secondary Ion Mass Spectrometry Imaging of Sulfur-Producing Enzymes inside Microglia Cells following Exposure to Silver Nanowires.

Analytical chemistry·2019
Same author

Identification and prospective stability of electronic nose (eNose)-derived inflammatory phenotypes in patients with severe asthma.

The Journal of allergy and clinical immunology·2018
Same author

Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort.

PloS one·2018
Same author

International research collaboration: The way forward.

Respirology (Carlton, Vic.)·2018
Same author

Exposure to Silver Nanospheres Leads to Altered Respiratory Mechanics and Delayed Immune Response in an <i>in Vivo</i> Murine Model.

Frontiers in pharmacology·2018

Related Experiment Video

Updated: Jul 16, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Inflammatory mediators in chronic obstructive pulmonary disease.

Kian F Chung1

  • 1National Heart & Lung Institute, Imperial College, London SW3 6LY, UK. f.chung@imperial.ac.uk

Current Drug Targets. Inflammation and Allergy
|February 20, 2007
PubMed
Summary

Chronic obstructive pulmonary disease (COPD) involves airway obstruction and inflammation. Key inflammatory mediators like IL-6 and TNF-alpha are elevated, contributing to tissue damage and mucus production in COPD patients.

Area of Science:

  • Pulmonary Medicine
  • Immunology
  • Cell Biology

Background:

  • Chronic obstructive pulmonary disease (COPD) is defined by airflow obstruction and inflammation in the small airways.
  • It involves chronic bronchitis (mucus hypersecretion) and emphysema (parenchymal destruction), leading to fibrosis and tissue damage.
  • Inflammatory pathways are central to COPD pathogenesis, involving various mediators.

Purpose of the Study:

  • To elucidate the key inflammatory mediators and cellular processes involved in COPD.
  • To understand the molecular mechanisms driving mucus hypersecretion and tissue remodeling in COPD.
  • To identify potential therapeutic targets within the inflammatory cascade of COPD.

Main Methods:

  • Analysis of inflammatory mediators in patient sputum, including cytokines (IL-6, IL-1beta, TNF-alpha, IL-8) and chemokines (MCP-1, RANTES, eotaxin).

More Related Videos

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

Related Experiment Videos

Last Updated: Jul 16, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

  • Assessment of reactive oxygen species (ROS) and their impact on inflammatory gene expression.
  • Investigation of growth factors (TGF-beta, EGF) and their role in fibroblast proliferation and mucin production.

    • Main Results:

    • Elevated levels of IL-6, IL-1beta, TNF-alpha, and IL-8 were measured in COPD sputum, increasing during exacerbations.
    • Bronchiolar epithelium over-expressed MCP-1 and IL-8; IL-8 and LTB4 contribute to neutrophil chemotaxis.
    • ROS increased inflammatory mediator gene expression, while TNF-alpha and IL-1beta stimulated MMP-9 and tenascin production.
    • Increased TGF-beta and EGF expression promoted fibroblast proliferation and mucin gene expression.

    Conclusions:

    • COPD pathogenesis involves a complex interplay of inflammatory mediators, including cytokines, chemokines, ROS, and growth factors.
    • These mediators drive key pathological features of COPD such as inflammation, mucus hypersecretion, and tissue remodeling.
    • Targeting these specific inflammatory pathways may offer therapeutic strategies for managing COPD.